Immuron Ltd (stock)
(Note: A public offering: “Our ordinary shares are listed on the Australian Securities Exchange under the symbol “IMC.” On May 19, 2017, the closing price of our ordinary shares on the Australian Securities Exchange was AUD$0.53 per ordinary share, equivalent to $15.74 per ADS based on an exchange rate of AUD$1.00 to $0.7426 (as published by the Reserve Bank of Australia as of May 19, 2017).
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. Our lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune mediated diseases including fatty-liver diseases.
|Address||Suite 1, 1233 High Street, Armadale, Victoria, Australia 3143|
|Phone Number||+61 (0)3 9824 5254|
|View Prospectus:||Immuron Ltd (stock)|
|Revenues||$0.9 mil (last 12 months)|
|Net Income||$-5.8 mil (last 12 months)|
|Price range||$9.99 - $9.99|
|Est. $ Volume||$6.1 mil|
|Manager / Joint Managers||Joseph Gunnar/ Rodman & Renshaw (a unit of H.C. Wainwright & Co.)|
|Expected To Trade:||6/9/2017|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|